Leukemia clinical trials in South Carolina

14 actively recruiting leukemia trials at 13 sites across South Carolina.

Data from ClinicalTrials.gov · last refreshed 2026-08-10

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full leukemia transparency page →

Payments from the drug maker running this trial to its lead doctors

CMS Open Payments · 2024

Loxo Oncology, Inc. funds and runs this clinical trial (NCT05254743). In 2024, Loxo Oncology, Inc. reported paying the doctors leading the trial a total of $2,037,139 for research work on this study.

Who paid

Eli Lilly and Company $2,037,139

Paid for research work on this trial

RICHY AGAJANIAN(oncologist on CancerDrs) $243,858
SALEHA SAJID(oncologist on CancerDrs) $165,169
CHANH HUYNH(oncologist on CancerDrs) $153,966
BRUCE CHESON(oncologist on CancerDrs) $152,368
JENNIFER CULTRERA(oncologist on CancerDrs) $151,740

Questions a patient might reasonably ask

Who is funding this trial, and how does the funding company stand to benefit if the trial succeeds?
Does my oncologist have a financial relationship with the trial sponsor outside of this trial?
Are there non-industry-sponsored trials (NIH, cooperative group) for my condition I should consider?
What are the alternative standards of care I should compare against enrolling here?

Research payments are not, by themselves, a conflict — paying for legitimate trial work is how drug development gets funded. The purpose of Sunshine Act disclosure is to give patients the context, not to make the decision for them.

Source: CMS Open Payments · ClinicalTrials.gov · Dispute process · How we compute this

As displayed on 2026-04-21. Corrections flow from the manufacturer through CMS and are adopted on our next refresh.

Payments from the drug maker running this trial to its lead doctors

CMS Open Payments · 2024

Grifols Therapeutics LLC funds and runs this clinical trial (NCT05645107). In 2024, Grifols Therapeutics LLC and 1 other company reported paying the doctors leading the trial a total of $77,372 for research work on this study.

Who paid

Grifols Therapeutics LLC $58,980
Grifols Biologicals LLC $18,393

Paid for research work on this trial

JOLAN WALTER $23,400
DARLA LILES(oncologist on CancerDrs) $22,780
NASHAT GABRAIL $18,958
FELIPE GASCON-RODON $5,000
TODD SHENKENBERG(oncologist on CancerDrs) $4,450

Questions a patient might reasonably ask

Who is funding this trial, and how does the funding company stand to benefit if the trial succeeds?
Does my oncologist have a financial relationship with the trial sponsor outside of this trial?
Are there non-industry-sponsored trials (NIH, cooperative group) for my condition I should consider?
What are the alternative standards of care I should compare against enrolling here?

Source: CMS Open Payments · ClinicalTrials.gov · Dispute process · How we compute this

As displayed on 2026-04-21. Corrections flow from the manufacturer through CMS and are adopted on our next refresh.

Phase 3 Recruiting NIH

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT04269902

Sites in South Carolina:

Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
Ralph H Johnson VA Medical Center — Charleston, South Carolina
Medical University of South Carolina — Charleston, South Carolina
Prisma Health Cancer Institute - Easley — Easley, South Carolina
Prisma Health Cancer Institute - Butternut — Greenville, South Carolina

View on ClinicalTrials.gov →

Phase 3 Recruiting Network

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs …

Sponsor: Children's Oncology Group

NCT ID: NCT04293562

Sites in South Carolina:

Medical University of South Carolina — Charleston, South Carolina
Prisma Health Richland Hospital — Columbia, South Carolina
BI-LO Charities Children's Cancer Center — Greenville, South Carolina

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st r…

Sponsor: PedAL BCU, LLC

NCT ID: NCT05183035

Sites in South Carolina:

Prisma Health Richland Hospital — Columbia, South Carolina

View on ClinicalTrials.gov →

Phase 2, Phase 3 Recruiting Industry

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms. Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at es…

Sponsor: Taiho Oncology, Inc.

NCT ID: NCT04256317

Sites in South Carolina:

Hollings Cancer Center — Charleston, South Carolina

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …

Sponsor: Loxo Oncology, Inc.

NCT ID: NCT05254743

Sites in South Carolina:

Prisma Health Cancer Institute — Greenville, South Carolina

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in B-cell CLL, …

Sponsor: Grifols Therapeutics LLC

NCT ID: NCT05645107

Sites in South Carolina:

GC2202 Study Site 110 — Rockville, South Carolina

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myelo…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05564390

Sites in South Carolina:

Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
Medical University of South Carolina — Charleston, South Carolina
Prisma Health Cancer Institute - Easley — Easley, South Carolina
Prisma Health Cancer Institute - Butternut — Greenville, South Carolina
Prisma Health Cancer Institute - Faris — Greenville, South Carolina

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia a…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06317649

Sites in South Carolina:

Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
Medical University of South Carolina — Charleston, South Carolina
Prisma Health Cancer Institute - Easley — Easley, South Carolina
Prisma Health Cancer Institute - Butternut — Greenville, South Carolina
Prisma Health Cancer Institute - Faris — Greenville, South Carolina

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT04546399

Sites in South Carolina:

Prisma Health Richland Hospital — Columbia, South Carolina
BI-LO Charities Children's Cancer Center — Greenville, South Carolina
Prisma Health Cancer Institute - Eastside — Greenville, South Carolina

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05554393

Sites in South Carolina:

Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
Prisma Health Cancer Institute - Easley — Easley, South Carolina
Prisma Health Cancer Institute - Butternut — Greenville, South Carolina
Prisma Health Cancer Institute - Faris — Greenville, South Carolina
Prisma Health Cancer Institute - Eastside — Greenville, South Carolina

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

This phase II MYELOMATCH treatment trial compares the effect of venetoclax to gemtuzumab ozogamicin, when given with cytarabine and daunorubicin ("7+3" regimen), for the treatment of patients with core binding factor acute myeloid leukemia…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06917911

Sites in South Carolina:

Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
Prisma Health Cancer Institute - Easley — Easley, South Carolina
Prisma Health Cancer Institute - Butternut — Greenville, South Carolina
Prisma Health Cancer Institute - Faris — Greenville, South Carolina
Prisma Health Cancer Institute - Eastside — Greenville, South Carolina

View on ClinicalTrials.gov →

Phase 1 Recruiting Academic/Other

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study …

Sponsor: Institut de Recherches Internationales Servier

NCT ID: NCT02074839

Sites in South Carolina:

Medical University of South Carolina — Charleston, South Carolina

View on ClinicalTrials.gov →

NA Recruiting Network

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.

Sponsor: Eastern Cooperative Oncology Group

NCT ID: NCT05108298

Sites in South Carolina:

AnMed Health Cancer Center — Anderson, South Carolina
Saint Joseph's/Candler - Bluffton Campus — Bluffton, South Carolina
Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
Prisma Health Cancer Institute - Easley — Easley, South Carolina
Gibbs Cancer Center-Gaffney — Gaffney, South Carolina

View on ClinicalTrials.gov →

Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.

NCT ID: NCT03452774

Sites in South Carolina:

Massive Bio SYNERGY-AI site — Greenville, South Carolina

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-10